blue cross glp-1 Blue Shield of Massachusetts will stop covering popular drugs for weight loss. Here's why How Health Plans Decide Which

Where semaglutide users might lose 15 pounds in their first month, sermorelin users might see 3 to 5 pounds of fat loss over the same period, potentially offset by muscle gain that masks the fat loss on the scale

Diabetic polyneuropathy (DPN) is the most common late complication of diabetes mellitus

It acts on melanocortin receptors and has been studied in research settings for its effects on melanogenesis and skin pigmentation pathways

So if the scale has stalled, you're in good companyand it doesn't mean the medication stopped working

The program: Began July 1, 2026 Is currently scheduled to continue through December 31, 2027 Is available nationwide Requires enrollment in Medicare Part D Operates outside the standard Medicare Part D prescription drug benefit Instead of using the normal Part D payment process, CMS administers the demonstration through a separate payment system